Breadcrumb

[A19-37] Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2019-04-18 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 554 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A19-79] Dapagliflozin (type 1 diabetes mellitus) - Addendum to Commission A19-37
Status: Commission completed

[A19-53] Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A17-65] Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed

[A12-18] Dapagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-08-01 Extract of dossier assessment 554 kBPDFdownload file
2019-08-01 Dossier assessment (German version) 849 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V [PDF, 554 kB]

Health information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Dapagliflozin (Forxiga, Farxiga) for the treatment of diabetes

Federal Joint Committee (G-BA)

2019-10-17 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close